abstract

Molecular Drivers of Oncotype DX, Prosigna, **EndoPredict, and the Breast Cancer Index: A TransATAC Study** Richard Buus, PhD^{1,2}; Ivana Sestak, PhD³; Ralf Kronenwett, MD, PhD⁴; Sean Ferree, PhD⁵; Catherine A. Schnabel, PhD⁶; Frederick L. Baehner, MD^{7,8}; Elizabeth A. Mallon, MBChB⁹; Jack Cuzick, PhD³; and Mitch Dowsett, PhD^{1,2}

PURPOSE The Oncotype DX Recurrence Score (RS), Prosigna Prediction Analysis of Microarray 50 (PAM50) Risk of Recurrence (ROR), EndoPredict (EP), and Breast Cancer Index (BCI) are used clinically for estimating risk of distant recurrence for patients receiving endocrine therapy. Discordances in estimates occur between them. We aimed to identify the molecular features that drive the tests and lead to these differences.

PATIENTS AND METHODS Analyses for RS, ROR, EP, and BCI were conducted by the manufacturers in the TransATAC sample collection that consisted of the tamoxifen or anastrozole arms of the ATAC trial. Estrogen receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative cases without chemotherapy treatment were included in which all four tests were available (n = 785). Clinicopathologic features included in some tests were excluded from the comparisons. Estrogen, proliferation, invasion, and HER2 module scores from RS were used to characterize the respective molecular features. Spearman correlation and analysis of variance tests were applied.

RESULTS There were moderate to strong correlations among the four molecular scores ($\rho = 0.63 \cdot 0.74$) except for RS versus ROR ($\rho = 0.32$) and RS versus BCI ($\rho = 0.35$). RS had strong negative correlation with its estrogen module ($\rho = -0.79$) and moderate positive correlation with its proliferation module ($\rho = 0.36$). RS's proliferation module explained 72.5% of ROR's variance, while the estrogen module explained only 0.6%. Most of EP's and BCI's variation was accounted for by the proliferation module (50.0% and 54.3%, respectively) and much less by the estrogen module (20.2% and 2.7%, respectively).

CONCLUSION In contrast to common understanding, RSs are determined more strongly by estrogen-related features and only weakly by proliferation markers. However, the EP, BCI, and particularly ROR scores are determined largely by proliferative features. These relationships help to explain the differences in the prognostic performance of the tests.

J Clin Oncol 39:126-135. © 2020 by American Society of Clinical Oncology

Licensed under the Creative Commons Attribution 4.0 License

INTRODUCTION

ASSOCIATED CONTENT See accompanying editorial on page 100

Appendix

Author affiliations and support information (if applicable) appear at the end of this article.

Accepted on September 28, 2020 and published at ascopubs.org/journal/ ico on October 27, 2020: DOI https://doi. org/10.1200/JC0.20. 00853

During the past 15 years, several multiparameter genomic tests have entered mainstream care for patients with early breast cancer, with some being endorsed for use by authoritative guidelines groups (ASCO, National Institute for Health and Care Excellence).^{1,2} The predominant use of the tests is in the management of estrogen receptor (ER)-positive primary disease. All approved tests show prognostic ability that is beyond that provided by standard clinicopathologic factors such that patients in whom the tests indicate excellent prognosis may safely be excluded from the administration of chemotherapy. The Oncotype DX Recurrence Score (RS; Genomic Health, Redwood City, CA) has 16 genes that characterize tumor biology along with five reference genes and has been the most widely used test.

Other tests include the Prediction Analysis of Microarray 50 (PAM50) Risk of Recurrence (ROR) score (Prosigna: NanoString Technologies, Seattle, WA),³ EndoPredict (EP; Myriad Genetics, Cologne, Germany),⁴ Breast Cancer Index (BCI; Biotheranostics, San Diego, CA),⁵ and MammaPrint⁶ (Agendia, Amsterdam, the Netherlands) that measure 46, 8, 7, and 70 genes, respectively, to characterize tumor biology in addition to reference genes. All but the last of these provide an estimate of residual risk of distant recurrence on the basis that patients will receive 5 years of adjuvant endocrine therapy. MammaPrint provides a prognostic estimate if no adjuvant treatment is to be administered. Understanding the molecular drivers of each of these tests and how they differ among the tests is key to interpreting discrepant estimates of risk that are made in many cases.7,8



Journal of Clinical Oncology®

Downloaded from ascopubs.org by Duke University--Durham on March 13, 2021 from 152.016.191.123 Copyright © 2021 American Society of Clinical Oncology. All rights reserved.



CONTEXT

Key Objective

We investigated the reasons for the frequently observed differences in estimates of risk of distant recurrence provided by four widely used commercial molecular profiling tests—Onco*type* DX Recurrence Score (RS), Prosigna Risk of Recurrence (ROR), EndoPredict (EP), and Breast Cancer Index (BCI)—in the TransATAC cohort.

Knowledge Generated

There were strong correlations among the four scores except for RS versus ROR and RS versus BCI. The differences among the tests were due to RS, against expectations, being dominated by its information on estrogen signaling, and ROR, also against expectations, being dominated by information on proliferation, while there was an intermediate position for the EP and BCI.

Relevance

These results should help clinicians to understand the reasons for different estimates of risk for individual patients and may allow them to give greater weighting to one result over another, depending on the clinical context.

It is widely believed that the RS is dominated by its proliferation module because five of the prognostic 16 genes in the test sit in the proliferation module and because it has the largest coefficient of each of the components of the integrative algorithm.⁹ An analysis of publicly available gene expression data from multiple studies involving approximately 3,000 patients supported the view of the importance of proliferation genes in the RS.¹⁰ It should be noted, however, that a threshold is applied to the numeric value given to the prognostic module such that only those cases with a score above that threshold are differentiated from one another on the basis of proliferation.⁹ We have drawn upon the TransATAC data set of 785 ER-positive/human epidermal growth factor receptor 2 (HER2)-negative primary breast cancers to examine the degree to which proliferation does in fact drive the RS and other molecular tests in their commercial form as well as consider other features of the tests that could explain discordances.

PATIENTS AND METHODS

Data were available from TransATAC, a translational study of samples collected from patients with hormone receptor–positive early-stage breast cancer treated with 5 years of tamoxifen or anastrozole in the ATAC randomized clinical trial.¹¹ Women were excluded from this analysis if they received chemotherapy or had HER2-positive disease. This study was approved by the South East London Research Ethics Committee. All patients provided written informed consent for their tissue to be used in translational research.

RNA was extracted as described before.¹² The four tests included in the current study were the RS, EP, Prosigna ROR, and BCI. Of note, the last three tests include clinical factors in their overall score (EP and ROR for all patients, BCI for node-positive disease), but for the purposes of this study, only the molecular component of the respective

score was assessed. Molecular analyses were conducted by the commercial providers of the respective scores using RNA extracted by Genomic Health.¹² The relationship of the risk estimates with prognosis in the TransATAC sample set has been described before.¹²⁻¹⁵ For a sample to be included in the current analysis, data on all four prognostic scores had to be available.

To study associations between continuous variables, Spearman's rank correlation was used. An analysis of variance of components of the RS score was conducted. Genes that constitute the RS modules are listed in Appendix Table A1 (online only). All statistical analyses were performed with R 3.6.1 software (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS

Molecular and clinical data were available for analysis from 785 samples. Clinical characteristics of this cohort are listed in Table 1. All patients were postmenopausal at diagnosis; 55.8% of the tumors were < 2 cm, and 21.4%, 60.3%, and 18.3% were low, intermediate, and high grade, respectively. The distribution of the molecular scores and the modules of the RS are listed in Appendix Table A2 (online only). The median values were 15.3 (interquartile range [IQR], 10.2-22.7) for RS, 40.2 (IQR, 23.5-56.3) for ROR, 5.5 (IQR, 4.2-7.0) for EP, and 4.8 (IQR, 3.7-5.9) for BCI. Using the original cutoffs, RS categorized 481, 222, and 82 patients into the low-, intermediate-, and high-risk groups, respectively. On the basis of the cutoffs used in the TAILORx trial, there were 231, 412, and 142 patients in the low-, intermediate-, and high-risk categories, respectively.

Relationship of RS, ROR, EP, and BCI Molecular Scores With Clinicopathologic Characteristics

The correlation of each of the scores with patient age, tumor size, nodal status, and grade is shown in Figure 1. Each of

Chara	cte	ristic				No.	(%
TABLE	1.	Clinical	Characteristics	of the	TransATAC	Cohort	

Gilaracteristic	NU. (76)
No. of patients	785
Age, years	
Mean (SD)	64.4 (8.2)
Range	46.7-88.8
BMI, kg/m ² (63 missing values)	
Mean (SD)	27.2 (4.9)
Range	15.9-49.4
Race	
White	779 (99.2)
Non-White	6 (0.8)
Nodal status	
NA	27 (3.4)
0	541 (68.9)
1-3	175 (22.3)
≥ 4	42 (5.4)
Tumor size, cm	
< 1	68 (8.7)
1 to < 2	370 (47.1)
2 to < 5	328 (41.8)
≥ 5	19 (2.4)
Grade	
Low	168 (21.4)
Intermediate	473 (60.3)
High	144 (18.3)
Treatment	
Radiotherapy	548 (69.8)
Mastectomy	315 (40.1)
Molecular score	
RS	
Mean (SD)	17.4 (10.8)
Range	0-65.3
ROR	
Mean (SD)	41.1 (20.6)
Range	2.0-93.5
EP	
Mean (SD)	5.8 (2.2)
Range	1.0-13.6
BCI	
Mean (SD)	4.8 (1.7)
Range	0.5-9.7

Abbreviations: BCI, Breast Cancer Index; BMI, body mass index; EP, EndoPredict; NA, not available; ROR, Risk of Recurrence; RS, Recurrence Score; SD, standard deviation. the scores showed a statistically significant relationship with grade. This was weak for the RS ($\rho = 0.27$) but moderate and similar for ROR, EP, and BCI ($\rho = 0.45$ -0.50). RS and EP showed no correlation > 0.20 with age, tumor size, or nodal status. However, the ROR correlated weakly and moderately with age and tumor size ($\rho = 0.29$ and 0.32, respectively), and the BCI had a correlation of 0.23 with tumor size. None of the signatures showed substantive correlations with nodal status.

Relationship Among RS, ROR, EP, and BCI Molecular Scores

The correlation of the overall risk scores with one another is shown in Figure 2. RS correlated strongly with EP ($\rho = 0.63$) and moderately with ROR ($\rho = 0.32$) and BCI ($\rho = 0.35$) across the whole population. Nonetheless, almost all patients with an RS \geq 31 had ROR and BCI scores above their respective median values (40.2 for ROR and 4.8 for BCI). Each of the other three scores correlated strongly with one another (ROR vEP, $\rho = 0.68$; ROR vBCI, $\rho = 0.74$; EP v BCI, $\rho = 0.67$).

Relationship Between RS and Its Constituent Modules

To explore the molecular features driving the risk scores that may account for the similarities and differences between them, the RS modules were used in additional comparisons. The estrogen module had a strong negative correlation with RS ($\rho = -0.79$). There was a moderate correlation between RS and its proliferation module ($\rho = 0.36$; Fig 3). When the proliferation module had thresholding applied at 6.5 as in the RS algorithm (ie, any proliferation module value < 6.5 was adjusted to 6.5 by the algorithm), 614 (78.2%) of 785 samples were allotted a value of 6.5. The correlation between RS and the proliferation module with thresholding was $\rho = 0.52$; in the set of 171 samples where the threshold was not applied (proliferation module > 6.5), the correlation was $\rho = 0.67$.

The invasion module had a weak positive association with RS ($\rho = 0.26$). There was either no association or a moderate association between RS and each of the three individual genes not assigned to any of the modules ($\rho = 0.14$ with *CD68*; $\rho = -0.43$ with *GSTM1*; $\rho = -0.36$ with *BAG1*; Appendix Fig A1, online only).

The HER2 module had no association with RS ($\rho = -0.04$) in this HER2-negative cohort. Of the 785 samples, 573 (73.0%) had HER2 module scores < 8.0 and had the threshold value of 8.0 applied. There was no association between the HER2 module and RS when the threshold was applied ($\rho = 0.16$), and in the set of 212 samples above the HER2 threshold, the correlation with RS was $\rho = 0.32$.

RS's comparisons with its components is not between independent measurements, and therefore, the observed correlations may be overstated. To perform a fair assessment of the contribution of the various molecular



FIG 1. Relationship of the Recurrence Score (RS), Risk of Recurrence (ROR), EndoPredict (EP), and Breast Cancer Index (BCI) molecular scores with clinical characteristics. Number of positive nodes > 10 was set to 10 in this figure. Spearman's ρ correlation coefficients are presented. Tumor sizes > 50 mm were set to 50 in this figure. Int, intermediate.

RS's variance was explained by its module compo-

features to their overall score, we assessed how much of RS's variance (59.1%), while the proliferation module accounted for approximately a fifth of RS's information nents. The estrogen module explained more than half of (19.4%; Table 2). In this cohort, both the invasion and the



FIG 2. Scatter plots and Spearman's p correlation coefficients of the Recurrence Score (RS), Risk of Recurrence (ROR), EndoPredict (EP), and Breast Cancer Index (BCI) molecular scores in TransATAC.

HER2 modules explained very little of RS's variance (1.3% and 2.2%, respectively).

Associations of ROR, EP, and BCI With the RS Proliferation, Estrogen, HER2, and Invasion Modules

We also analyzed the association of proliferation (unthresholded), estrogen, HER2 (unthresholded), and invasionrelated RS module scores with each of the ROR, EP, and BCI scores. Most of the ROR score's variance could be accounted for by RS's proliferation module score (72.5%) and none by RS's estrogen module score (0.6%; Table 2; Fig 4). Half of EP's variance was accounted for by the proliferation module (50.0%) and an additional 20.2% by the estrogen module. The BCI score's variation was largely accounted for by the proliferation module (54.3%) and almost none by the estrogen module (2.7%). Each of ROR, EP, and BCI had very little association with RS's HER2 module (explained variance range, 0.6%-2.4%), and although the correlation of each of these with the invasion module was > 0.3, the explained variance ranged between 0.3% and 0.7%.

DISCUSSION

The majority of patients with early ER-positive breast cancer will not experience a recurrence when treated with 5 years of adjuvant endocrine therapy.¹⁶ Finding the means to identify those patients such that they can safely be excluded from additional adjuvant chemotherapy and/or extended adjuvant endocrine therapy has been a high priority over recent years¹⁷ and has led to the development and widespread clinical use of several commercial multiparameter gene expression assays, including the four molecular assays studied here. It is therefore important that the oncologist interpreting and applying the scores for patient management have an understanding of the biologic features the tests reflect, particularly when trying to understand the difference among their readouts.

To our knowledge, this is the first four-way comparison of the assays in their commercial form aimed at evaluating their similarity and molecular drivers. Previously, we published the prognostic comparison of the four assays in



FIG 3. Relationship of the Recurrence Score (RS) with its module components. Spearman's p correlation coefficients are presented. HER2, human epidermal growth factor receptor 2; th, thresholded.

their commercial form.⁸ A number of articles have com- commercial assays is generally poorly documented. Dispared some of the assays,^{7,18-20} but these have been of cordant risk stratification in these studies, however, support limited sample size and/or based around research as- our observations of varying agreement among the molecsays for which comparability with the clinically used

ular scores.

	ĸs		ROR		EP		BCI		
RS Module	Sum of Squares	Variance Explained (%)	Sum of Squares	Variance Explained (%)	Sum of Squares	Variance Explained (%)	Sum of squares	Variance Explained (%)	
Proliferation (unthresholded)	17,628	19.4	241,358	72.5	1,878	50.0	1,186	54.3	
Estrogen	53,656	59.1	1,799	0.5	759	20.2	59	2.7	
Invasion	1,215	1.3	1,610	0.5	24	0.7	5	0.3	
HER2 (unthresholded)	1,948	2.2	4,371	1.3	23	0.6	51	2.4	
Residuals	16,349	18.0	83,882	25.2	1,067	28.4	880	40.3	

TABLE 2. Variance of RS, ROR, BCI, and EP Scores as Accounted for by RS's Four Modules

NOTE. Residuals show the amount of variance not accounted for by RS's four modules.

Abbreviations: BCI, Breast Cancer Index; EP, EndoPredict; HER2, human epidermal growth factor receptor 2; ROR, Risk of Recurrence; RS, Recurrence Score.

Journal of Clinical Oncology



FIG 4. Associations of the (A) Risk of Recurrence (ROR), (B) EndoPredict (EP), and (C) Breast Cancer Index (BCI) with the proliferation, estrogen, human epidermal growth factor receptor 2 (HER2), and invasion modules of the Recurrence Score (RS). Spearman's ρ correlation coefficients are presented.

The availability of the individual gene and gene module scores that constitute the Onco*type* DX RS provided a unique opportunity to study the degree to which the RS is driven by these individual features. Using the RS genes and gene modules as surrogate measures of the designated biologic features, we were also able to identify the major differences in the molecular drivers that lead to overall differences and similarities among the scores.

Of note, this study focused entirely on the molecular components of the tests and did not include the clinicopathologic features that are integrated into the final prognostic result for the ROR, EP, and BCI. We found that other than the relationship of each score with grade, they had little relationship with the other features we considered (age, tumor size, nodal status). Given that these features are known to have strong prognostic significance, their statistical independence from each of the scores underlines the potential for including them in a composite score for optimal prognostic estimates as we have previously published for the RS-pathology-clinical assessment.²¹ The stronger correlation of ROR, EP, and BCI ($\rho = 0.45-0.50$) than RS ($\rho = 0.27$) with grade probably reflects the weaker association of RS with proliferation.

The much weaker association of RS with its proliferation module than with its estrogen module is superficially surprising given that the coefficient in the Cox model is three times greater for the proliferation than for the estrogen module.⁹ This is at least partly explained by the score from the proliferation module being thresholded such that in this series, only 22% of the patients had the proliferation module unthresholded and therefore contributed meaningfully to the final score. Thresholding of the proliferation module presumably reflects the prognostic importance of the modules as measured in the training set of RS.⁹ Our earlier analysis of the effect of thresholding on prognostic estimates with the RS showed the proliferation module being more informative when thresholding was applied.²² Practitioners should therefore not be surprised if a high RS tumor is associated with low proliferation as reflected, for example, by immunohistochemistry for protein encoded by the *MKI67* gene or low grade as reported here.

One might conclude that this TransATAC population is of relatively good prognosis. Patients who had received chemotherapy (on the basis of clinicopathologic factors) were excluded such that outcome for endocrine therapy alone could be assessed. However, we found that it is similar to a SEER cohort of > 40,000 patients in terms of risk as determined by RS reported by Petkov et al.²³ For patients with node-negative disease, 8.0% of the SEER population had RS \geq 31, which was actually lower than the 10.4% for the TransATAC cohort. Similarly, among patients with node-positive disease, 7.0% of the SEER population had RS \geq 31 compared with 11.1% in TransATAC (Appendix Table A3, online only). This is likely due to the lower chemotherapy use (9%) among UK patients on which the TransATAC collection is based compared with chemotherapy use in the overall ATAC cohort (21%).²⁴ As a consequence, the cohort presented here includes many patients who would have received chemotherapy had they been treated in other countries.

The strong inverse correlation of the RS with the estrogen module indicates that its eventual score is likely to be particularly influenced by the benefit patients receive from their endocrine therapy. It may also explain the finding in our earlier reports in TransATAC where the RS showed a marked reduction in its prognostic performance between 5 and 10 years, while the ROR, BCI, and EP all showed continued substantial separation.⁸ In TransATAC after 5 years, the estrogen module had no prognostic significance,²² consistent with patients who showed the strongest estrogen signaling at diagnosis who lost much of their benefit from endocrine therapy at its withdrawal. Along with the pronounced importance of the estrogen module to the overall RS, this change at 5 years would be expected to lead to profoundly reduced prognostic performance of the RS after 5 years. The degree to which this observation in TransATAC may be generalizable is not known, but it is supported by the data related to the switching of the importance of estrogen signaling at 5 years being very similar to that reported by Bianchini et al.²⁵ A meta-analysis from Early Breast Cancer Trialist Collaborative Group data of 74,194 women with primary ER-positive breast cancer who were scheduled to have received 5 years of endocrine therapy also found that higher progesterone receptor expression reflected better outcomes only in the first 5 years after surgery and not beyond 5 years.²⁶

The strongest relationship of the other three tests was with the proliferation module of RS, with proliferation accounting for most of the variance between 50.0% for EP to 72.5% for ROR. The latter very high value may seem surprising given that the derivation of the ROR is related to the degree of correlation of a given tumor to each of the intrinsic subtypes.²⁷ However, as well as these correlations, the algorithm includes a component that is determined by the expression of 18 proliferation-related genes in the 50-gene panel.²⁸ Clearly, the weighting of that component results in scores in which proliferation is the dominant feature.

Our study has a number of strengths. The assays were carried out by the developers of the commercial assays who used their proprietary methods and were blinded to the patients' clinical and outcome data. The same batch of RNA extracts were used for all four assays, which allowed for direct head-to-head comparisons of the scores and features. Weaknesses include that the module scores analyzed in this study are surrogates of the biologic features we assessed and that their direct role can be considered only with the RS. Nonetheless, the very strong relationships with proliferation and the individual genes of the estrogen module being those that are strongly related to estrogen signaling support the value of these surrogates. Furthermore, > 99% of the cohort was recorded as White, and this poses some limitation on the generalizability of the findings to racially more diverse populations.

In summary, we found that despite common thinking, the Onco*type* DX RS was primarily driven by estrogen-related rather than proliferation-related features in the majority of tumors in the TransATAC cohort. This is in contrast with the ROR, EP, and BCI that were dominated by proliferative features. The generalizability of these findings is supported by the similarity between the range of RSs in the analyzed population and that in the SEER database. These findings may explain the differences and similarities in the prognostic performance of these tests for early and late recurrence that we and others have reported.

AFFILIATIONS

¹The Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, London, United Kingdom

²Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital, London, United Kingdom

³Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom

Journal of Clinical Oncology

Buus et al

⁴Myriad International GmbH, Cologne, Germany
 ⁵NanoString Technologies, Seattle, WA
 ⁶Biotheranostics, San Diego, CA
 ⁷Genomic Health, Redwood City, CA
 ⁸Department of Pathology, University of California, San Francisco, San Francisco, CA

⁹Department of Pathology, Southern General Hospital, Glasgow, United Kingdom

CORRESPONDING AUTHOR

Richard Buus, PhD, The Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, 237 Fulham Rd, London SW3 6JB, UK; Twitter: @ICR_London; e-mail: richard.buus@icr.ac.uk.

PRIOR PRESENTATION

Presented at the 42nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-14, 2018.

SUPPORT

Supported by Breast Cancer Now working in partnership with Walk the Walk as well as by National Institute for Health Research Royal Marsden/ The Institute of Cancer Research Biomedical Research Centre and Cancer Research UK grant C569/A16891 (J.C.).

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI https://doi.org/10.1200/JC0.20.00853.

AUTHOR CONTRIBUTIONS

Conception and design: Richard Buus, Ivana Sestak, Mitch Dowsett **Provision of study material or patients:** Frederick L. Baehner, Elizabeth A. Mallon

Collection and assembly of data: Richard Buus, Ralf Kronenwett, Sean Ferree, Elizabeth A. Mallon

Data analysis and interpretation: Richard Buus, Ivana Sestak, Catherine A. Schnabel, Frederick L. Baehner, Elizabeth A. Mallon, Jack Cuzick, Mitch Dowsett

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

ACKNOWLEDGMENT

We thank Adam Brentnall of Queen Mary University of London for advising on the statistical analysis.

REFERENCES

- 1. Harris LN, Ismaila N, McShane LM, et al: Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline summary. J Oncol Pract 12:384-389, 2016
- National Institute for Health and Care Excellence: Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer, 2018. https:// www.nice.org.uk/guidance/dg34
- Wallden B, Storhoff J, Nielsen T, et al: Development and verification of the PAM50-based prosigna breast cancer gene signature assay. BMC Med Genomics 8: 54, 2015
- 4. Filipits M, Rudas M, Jakesz R, et al: A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17:6012-6020, 2011
- Jerevall PL, Ma XJ, Li H, et al: Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 104:1762-1769, 2011
- 6. Cardoso F, van't Veer LJ, Bogaerts J, et al: 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375:717-729, 2016
- 7. Bartlett JM, Bayani J, Marshall A, et al: Comparing breast cancer multiparameter tests in the OPTIMA prelim trial: No test is more equal than the others. J Natl Cancer Inst 108:djw050, 2016
- Sestak I, Buus R, Cuzick J, et al: Comparison of the performance of 6 prognostic signatures for estrogen receptor-positive breast cancer: A secondary analysis of a randomized clinical trial. JAMA Oncol 4:545-553, 2018
- 9. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
- 10. Wirapati P, Sotiriou C, Kunkel S, et al: Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10:R65, 2008
- 11. Cuzick J, Sestak I, Baum M, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135-1141, 2010
- Dowsett M, Cuzick J, Wale C, et al: Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: A TransATAC study. J Clin Oncol 28:1829-1834, 2010
- Dowsett M, Sestak I, Lopez-Knowles E, et al: Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31:2783-2790, 2013
- 14. Sgroi DC, Sestak I, Cuzick J, et al: Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: A prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 14:1067-1076, 2013
- Buus R, Sestak I, Kronenwett R, et al: Comparison of EndoPredict and EPclin with oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy. J Natl Cancer Inst 108:djw149, 2016
- 16. Davies C, Godwin J, Gray R, et al: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level metaanalysis of randomised trials. Lancet 378:771-784, 2011
- 17. Dowsett M, Goldhirsch A, Hayes DF, et al: International web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 9:R81, 2007
- 18. Varga Z, Sinn P, Fritzsche F, et al: Comparison of EndoPredict and oncotype DX test results in hormone receptor positive invasive breast cancer. PLoS One 8: e58483, 2013 [Erratum: PLoS One 8(10), 2013]
- 19. Alvarado MD, Prasad C, Rothney M, et al: A prospective comparison of the 21-gene recurrence score and the PAM50-based prosigna in estrogen receptorpositive early-stage breast cancer. Adv Ther 32:1237-1247, 2015
- Sinn P, Schneeweiss A, Endris V, et al: Intrinsic subtypes and risk scores in ER+/HER2-breast cancer: A comparison of prosigna and oncotypeDX risk categories with Ki67. Breast 32:S105, 2017

- 21. Tang G, Cuzick J, Costantino JP, et al: Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: Recurrence Score alone and integrated with pathologic and clinical factors. J Clin Oncol 29:4365-4372, 2011
- 22. Dowsett M, Sestak I, Buus R, et al: Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2negative breast cancer. Clin Cancer Res 21:2763-2770, 2015
- Petkov VI, Miller DP, Howlader N, et al: Breast-cancer-specific mortality in patients treated based on the 21-gene assay: A SEER population-based study. NPJ Breast Cancer 2:16017, 2016 [Erratum: NPJ Breast Cancer 6:17, 2018]
- 24. Dowsett M, Allred C, Knox J, et al: Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 26:1059-1065, 2008
- Bianchini G, Pusztai L, Karn T, et al: Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. Breast Cancer Res 15:R86, 2013
- 26. Pan H, Gray R, Braybrooke J, et al: 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377:1836-1846, 2017
- 27. Parker JS, Mullins M, Cheang MC, et al: Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167, 2009
- Nielsen TO, Parker JS, Leung S, et al: A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifentreated estrogen receptor-positive breast cancer. Clin Cancer Res 16:5222-5232, 2010

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Ivana Sestak

Honoraria: Myriad Genetics, NanoString Technologies, Pfizer Consulting or Advisory Role: Myriad Genetics

Ralf Kronenwett

Employment: Myriad International Stock and Other Ownership Interests: Siemens AG Patents, Royalties, Other Intellectual Property: Previous shareholder of Sividon Diagnostics GmbH (Myriad International GmbH) with milestone payment, patents with EndoPredict

Sean Ferree

Employment: NanoString Technologies Stock and Other Ownership Interests: NanoString Technologies Patents, Royalties, Other Intellectual Property: Inventor on multiple patents and patent applications for NanoString Technologies Travel, Accommodations, Expenses: NanoString Technologies

Catherine A. Schnabel

Employment: Biotheranostics Leadership: Biotheranostics Stock and Other Ownership Interests: Biotheranostics Research Funding: Biotheranostics (Inst) Patents, Royalties, Other Intellectual Property: Patents and intellectual property related to being employed by Biotheranostics (Inst) Travel, Accommodations, Expenses: Biotheranostics

Frederick L. Baehner

Employment: Exact Sciences Leadership: Exact Sciences Stock and Other Ownership Interests: Exact Sciences

Jack Cuzick

Research Funding: Becton Dickinson (Inst), Genera Biosystems (Inst), Myriad Genetics (Inst), AstraZeneca (Inst), Aventis (Inst), GeneFirst (Inst), Sanofi (Inst) Patents, Royalties, Other Intellectual Property: Royalties from Myriad Genetics to institution of which I receive a share for development of cell cycle progression score (Prolaris)

Mitch Dowsett

Honoraria: Myriad Genetics Consulting or Advisory Role: GTx, Radius Health, Orion Pharmaceuticals, G1 Therapeutics

Research Funding: Pfizer (Inst), Radius Health (Inst) Travel, Accommodations, Expenses: Pfizer, Myriad Genetics Other Relationship: Institute of Cancer Research

No other potential conflicts of interest were reported.

APPENDIX



FIG A1. Associations of the Recurrence Score (RS) with the three RS genes not assigned to RS module: CD68, GSTM1, and BAG1. Spearman's ρ correlation coefficients are presented.

THE AT. NO MODULES and denes that constitute the modules					
RS Module	Genes				
Proliferation	CCNB1, AURKA (STK15), BIRC5 (Survivin), MKI67, MYBL2				
Estrogen	ESR1, PGR, BCL2, SCUBE2				
Invasion	MMP11, CTSV (CTSL2)				
HER2	ERBB2 (HER2), GRB7				

TABLE A1. RS Modules and Genes That Constitute the Modules

Abbreviations: HER2, human epidermal growth factor receptor 2; RS, Recurrence Score.

Journal of Clinical Oncology

Score	Median	Q1	Q3	IQR
Molecular scores (theoretical range)				
RS (0-100)	15.4	10.2	22.7	12.5
ROR (0-100)	40.2	23.5	56.3	32.8
EP (0-15)	5.5	4.2	7.0	2.9
BCI (0-10)	4.8	3.7	5.9	2.2
RS modules				
Proliferation	5.8	5.2	6.4	1.2
Estrogen	9.1	8.5	9.8	1.3
Invasion	7.2	6.6	7.7	1.1
HER2	7.6	7.2	8.0	0.9
Proliferation thresholded	6.5	6.5	6.5	0.0
HER2 thresholded	8.0	8.0	8.0	0.0

TABLE A2. Quartile and IQR Values for the Molecular Scores and RSModules in TransATAC

Abbreviations: BCI, Breast Cancer Index; EP, EndoPredict; HER2, human epidermal growth factor receptor 2; IQR, interquartile range; Q, quartile; ROR, Risk of Recurrence; RS, Recurrence Score.

TABLE A3. Patients in RS Risk Categories in TransATAC and SEER

	RS Risk Group (cutoff points 18 and 31), No. (%)					
Patient Cohort	Low	Intermediate	High			
TransATAC						
All patients (n = 785)						
No.	481 (61.3)	222 (28.3)	82 (10.4)			
Median RS (IQR)	11.4 (7.8-14.5)	22.8 (19.8-36.3)	37.7 (34.0-45.4)			
Node negative (n = 541)						
No.	342 (63.2)	143 (26.4)	56 (10.4)			
Median RS (IQR)	11.4 (7.6-14.4)	22.7 (19.8-27.0)	37.6 (33.8-45.7)			
Node positive (n = 217)						
No.	124 (57.1)	69 (31.8)	24 (11.1)			
Median RS (IQR)	11.4 (7.8-14.9)	22.9 (19.8-25.1)	38.0 (35.0-45.0)			
SEER						
Node negative (n = $40,134$)	21,760 (54.2)	15,152 (37.8)	3,222 (8.0)			
Node positive (n = 4,691)	2,694 (57.4)	1,669 (35.6)	328 (7.0)			

NOTE. As reported by Petkov et al.23

Abbreviations: IQR, interquartile range; RS, Recurrence Score.

© 2020 by American Society of Clinical Oncology

Volume 39, Issue 2